Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

October 15, 2015 Leave a comment 2,763 Views

GHENT, Belgium, October 15, 2015 – Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Isis Pharmaceuticals

Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

Single-cell CUT&Tag to identify cell states in normal and disease tissue

The triumphs and limitations of computational methods for scRNA-seq

Researchers have assembled the most comprehensive RNA-atlas ever

More evidence that most cancer cells grown in a dish have little in common transcriptionally with cancer cells in people

SuperFreq – detecting copy number alterations in RNA-Seq using

RNA sequencing identifies trigger for ‘head-to-tail’ axis development in human embryo

How long-known genes continue to surprise researchers